Bladder Cancer Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working

Urine is stored in the bladder, which is a hollow organ in the lower abdomen. Bladder cancer develops in the bladder's lining. Transitional cell carcinoma, commonly known as urothelial carcinoma, is the most frequent type of bladder cancer. Smoking is one of the leading causes of bladder cancer. Bladder cancer is frequently detected in its early stages.

Bladder cancer was rated 10th among all cancers in the globe, with 549,000 new cases and 200,000 deaths each year; it contributed 3.4 percent to the overall cancer burden worldwide. There were 18,921 new cases and 10,231 deaths in India.

DelveInsight’s “Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bladder Cancer, historical and forecasted epidemiology as well as the Bladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Bladder Cancer Market Report:

  •  An Estimated 573,278 people were diagnosed with Bladder Cancer WorldWide in 2020

  •  Bladder Cancer is the fourth most common cancer among the men

  • There has been a decline of 1%/year in the number of cases of Bladder Cancer in the US from 2009-to 2018 

  • Bladder cancer was rated 10th among all cancers in the globe, with 549,000 new cases and 200,000 deaths each year 

  • While the specific aetiology of bladder cancer is unknown, it has been related to a number of risk factors, including tobacco use and exposure to certain chemicals and gases. In addition, persons who have a family history of bladder cancer are more likely to get the disease

Got queries? Click here to know more about the Bladder Cancer Market Landscape

Bladder Cancer Symptoms: 

  • Blood in the Urine can be seen

  • Pain is felt while urinating

  • Back Pain

  • Pain in The Pelvic area

Bladder Cancer Market: 

The dynamics of the Bladder Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecasted period 2018-2030. 

The key players working in the field of Bladder Cancer are the - Swiss Group for Clinical Cancer Research, University of Kansas Medical Center, University of Oklahoma, Radiation Therapy Oncology Group, National Cancer Institute (NCI), and ImmunityBio, Inc. 

Learn more by requesting for sample @ Bladder Cancer Market Landscape 

Bladder Cancer Pipeline Therapies:

  •  VPM1002BC

  • Ascorbic Acid

  • Avelumab

  • Cisplatin

  •  Paclitaxel

  • Mitomycin C

  • N-803 and BCG 

Bladder Cancer and Key Companies: 

  • Swiss Group for Clinical Cancer Research

  • University of Kansas Medical Center

  • University of Oklahoma

  • Radiation Therapy Oncology Group

  • National Cancer Institute (NCI)

  • ImmunityBio, Inc. 

Click here to read more about Bladder Cancer Market Outlook 2032

Related Reports: 

Bladder Cancer Pipeline 

 "Bladder Cancer Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bladder Cancer market. A detailed picture of the Bladder Cancer pipeline landscape is provided, which includes the disease overview and Bladder Cancer treatment guidelines. 

Bladder Cancer Epidemiology 

DelveInsight's 'Bladder Cancer  Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Bladder Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports By Delveinsight:

Comments

Post a Comment

Popular posts from this blog

Raising the Bar: ADCs and Lung Cancer Treatment Breakthroughs

Image
  The ENHERTU Effect: A Closer Look at the Dynamic Duo Daiichi Sankyo and AstraZeneca Taking on HER2-mutant NSCLC Lung cancer remains one of the most challenging and prevalent forms of cancer. Within this landscape, innovative treatments are offering new hope. One such breakthrough is the collaboration between Daiichi Sankyo and AstraZeneca, which brings forth ENHERTU, an Antibody-Drug Conjugate (ADC). ENHERTU is making strides in targeting HER2-mutant Non-Small Cell Lung Cancer (NSCLC), a rare and challenging subset of the disease. The ENHERTU partnership aims to address this unmet medical need with a highly targeted approach. Dato-DXd vs. TRODELVY: The Battle of ADC Targeting TROP2 As the world of ADCs expands, another remarkable battle is brewing between Daiichi Sankyo's Dato-DXd and TRODELVY in their quest to target TROP2. TROP2, also known as CEACAM5, is an antigen overexpressed in various cancers, including endometrial cancer. Both ADCs hold the potential to transform the
Read more
Image
Covering the Therapeutic Advancements in Obstructive Sleep Apnea Treatment Scenario Obstructive Sleep Apnea (OSA) is a common chronic sleep disorder, which is characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep, leading to a complete or partial obstruction of the airway, results of which are apneas, hypopneas, or sometimes both. Obstructive sleep apnea is a chronic and permanent condition, through proper therapy and medications the condition can be cured. Almost every system in the body is affected by Obstructive Sleep Apnea, resulting in an increased incidence of hypertension, stroke, altered immune system, and cardiovascular disease.  Obstructive Sleep Apnea is caused when the throat muscles relax during sleep, which causes the tissue in the back of the throat to collapse and block the upper airway. Daytime sleepiness is one of the most common symptoms of Obstructive Sleep Apnea. People affected with Obstructive Apnea also complain of memory pro
Read more

Market Drivers and Barriers for Vascular Stents: An In-Depth Analysis

Image
  What are Vascular Stents? Vascular stents are medical devices that are used to treat narrow or blocked blood vessels. They are small, mesh-like tubes that are inserted into the affected artery to help prop it open and improve blood flow. The global vascular stents market is expected to grow significantly in the coming years due to an increase in the prevalence of cardiovascular diseases, technological advancements in stent design, and the growing aging population. Vascular Stents Market Size and Forecast The global vascular stents market size is expected to reach USD 16.52 billion by 2028, growing at a CAGR of 6.7% from 2021 to 2028. North America dominates the market due to a high prevalence of cardiovascular diseases, increased healthcare spending, and better healthcare infrastructure. Vascular Stents Market Trends and Analysis The market is experiencing a shift towards the development of bioresorbable stents that dissolve within the body after the artery has healed. This reduces
Read more